Carson City, NV
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Clayton Medical Research Foundation Inc, founded in 1989, is a community nonprofit that reported $2.8M in total revenue in fiscal year 2023. Expenses of $3.9M exceeded revenue, resulting in a 38% operating deficit.
As a supporting organization to the Clayton Foundation for Research ("Clayton") the Foundation's primary mission is to fund medical research for the purpose of discovering the cause, prevention and cure of diseases for the benefit of mankind. The secondary mission is to transfer the resulting medical research discoveries from the laboratory to the use of the general public by patenting and licensing such technology for development into drugs or other products for the use and benefit of mankind through Clayton's other supporting entities.
The Tumor Targeting Toxins grant to the University of California, San Diego, funds research directed to the discovery and development of compounds for cancer therapy, compounds synthesized with...
The Tumor Targeting Toxins grant to the University of California, San Diego, funds research directed to the discovery and development of compounds for cancer therapy, compounds synthesized with proteins joined by a sortase reaction, and compounds with cancer stem cell and hormone targeting ligands coupled with toxins for delivery to ovarian tumors and other epithelial tumors. Patent applications have been filed for these technologies by Research Development Foundation ("RDF"), a tax-exempt supporting organization of the Foundation {see Schedule R, Part III), and collaborations have been and are being established with other scientists and with commercial entities and consultants for manufacturing and development of drugs for human cancer indications.
The MorfVeuss Discovery, Screening and Therapeutic Platform grant to the Salk Institute for Biological Studies funds research to develop a screening platform, called MorfVeuss, that will allow the...
The MorfVeuss Discovery, Screening and Therapeutic Platform grant to the Salk Institute for Biological Studies funds research to develop a screening platform, called MorfVeuss, that will allow the discovery of micro-peptide drug targets while transforming these discoveries into gene and oncolytic viral therapeutic candidates. The objective of this platform is to overcome a critical unmet need in identifying and characterizing a novel class of therapeutics, building from very recent discoveries in the past decade in the emerging field of micro-proteins. Development of this platform should open the door for new breakthroughs and a pipeline of innovative new drug candidates, applicable across different indications.
STF-1 and Glucose Control grant to The Salk Institute for Biological Studies focuses on characterization of cellular proteins that modulate fatty acid metabolism in muscle and fat; characterization...
STF-1 and Glucose Control grant to The Salk Institute for Biological Studies focuses on characterization of cellular proteins that modulate fatty acid metabolism in muscle and fat; characterization of a signaling module that promotes beta cell survival; and the role of PDX and other known and new molecular switches in promoting beta islet cell proliferation and insulin secretion in the pancreas and liver.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $2,839,778 | $2,968,221 | 0.0% |
| Expenses | $3,913,882 | $2,947,932 | +0.3% |
| Net Income | $-1,074,104 | $20,289 | -53.9% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Robert M Wallace | Trustee, President | 8.00 |
Officer
Director
|
$13,813 | $97,800 | $761,256 |
| Jarred W Sloan | Trustee, Vice President, Treasurer | 6.00 |
Officer
Director
|
$13,813 | $97,800 | $761,256 |
| Lynn P Carter | Trustee | 4.00 |
Director
|
$13,813 | $97,800 | $761,256 |
| Joan S Dunlap | Trustee,VP,Assistant Secretary | 4.00 |
Officer
Director
|
$9,920 | $88,019 | $588,105 |
| Brian W Crozier | Trustee, Chairman | 2.00 |
Officer
Director
|
$13,813 | $50,086 | $395,392 |
| Thomas J Brorby Deceased | Trustee, Chairman | 2.00 |
Officer
Director
|
$11,479 | $16,600 | $303,562 |
| Robert L Evans | VP, Assistant Treasurer | 0.00 |
Officer
|
$0 | $81,846 | $291,846 |
| John Russell Beekman | Vice President | 10.00 |
Officer
|
$0 | $39,925 | $153,603 |
| Christopher MacKenzie | Vice President, Secretary | 1.00 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $2,839,778 | $3,913,882 | $88,853,594 | $-1,074,104 |
| 2022 | $2,968,221 | $2,947,932 | $77,997,012 | $20,289 |
| 2021 | $3,301,602 | $3,411,349 | $95,559,460 | $-109,747 |
| 2020 | $1,906,095 | $3,147,844 | $82,610,089 | $-1,241,749 |
Compare Clayton Medical Research Foundation Inc with other nonprofits in Nevada and across the country.